Aptamers: The emerging class of future anticoagulation for vascular disease

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 4, 2010, Pages 503-507

  Kuliczkowski, Wiktor ^a,b   Floyd, James ^a   Malinin, Alex ^a   Serebruany, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Anticoagulants; Aptamer; Clinical trial; Oligonucleotides

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; APTAMER; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR 9A APTAMER; CLOPIDOGREL; DNA APTAMER; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; RB 006; RB 007; RNA APTAMER; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; COMBINATORIAL CHEMISTRY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; FEVER; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIRUS INFECTION; VIRUS REPLICATION;

ANTICOAGULANTS; ANTIDOTES; APTAMERS, NUCLEOTIDE; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; VASCULAR DISEASES;

EID: 77951218739     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.182     Document Type: Review

References (28)

1. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
2. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289, 853-863 (2003). (Pubitemid 37430344)
3. Moscucci M. Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J. Invasive Cardiol. 14(Suppl. B), 55B-64B (2002). (Pubitemid 34304133)
4. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann. Thorac. Surg. 74, 1180-1186 (2002). (Pubitemid 35176743)
5. Granger CB, Hirsch J, Califf RM et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93, 870-878 (1996). (Pubitemid 126425250)
6. Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology 102, 308-314 (2005). (Pubitemid 40189077)
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 311S-337S (2004). (Pubitemid 39297959)
8. Teoh KH, Young E, Bradley CA, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 88, II420-II425 (1993). (Pubitemid 23324594)
9. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 352, 777-785 (2005). (Pubitemid 40271172)
10. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822 (1990). (Pubitemid 20272100)
11. Marciniak RA, Garcia-Blanco MA, Sharp PA. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc. Natl Acad. Sci. USA 87, 3624-3628 (1990). (Pubitemid 20173689)
12. Cullen BR, Greene WC. Regulatory pathways governing HIV-1 replication. Cell 58, 423-426 (1989).
13. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65, 6811-6816 (1991).
14. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990). (Pubitemid 20248891)
15. Beigelman L, McSwiggen JA, Draper KG et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. 270, 25702-25708 (1995).
16. Willis MC, Collins BD, Zhang T et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 9, 573-582 (1998). (Pubitemid 28437001)
17. Rusconi CP, Scardino E, Layzer J et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94 (2002). (Pubitemid 34987876)
18. Chan MY, Cohen MG, Dyke CK et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117, 2865-2874 (2008).
19. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
20. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566 (1992).
21. DeAnda A Jr, Coutre SE, Moon MR et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. 58, 344-350 (1994).
22. Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J. Mol. Biol. 272, 688-698 (1997). (Pubitemid 27448187)
23. White R, Rusconi C, Scardino E et al. Generation of species cross-reactive aptamers using 'toggle' SELEX. Mol. Ther. 4, 567-573 (2001). (Pubitemid 34026872)
24. Rusconi CP, Yeh A, Lyerly HK, Lawson JH, Sullenger BA. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb. Haemost. 84, 841-848 (2000).
25. Gal SW, Amontov S, Urvil PT et al. Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. Eur. J. Biochem. 252, 553-562 (1998). (Pubitemid 28156881)
26. Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc. Med. 13, 39-45 (2003).
27. Dyke CK, Steinhubl SR, Kleiman NS et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a Phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490-2497 (2006).
28. Kubik MF, Stephens AW, Schneider D, Marlar RA, Tasset D. High-affinity RNA ligands to human a-thrombin. Nucleic Acids Res. 22, 2619-2626 (1994). (Pubitemid 24222442)